Theravance gets a fresh start
Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Theravance fails its first big test
A flop for the gut-selective Jak inhibitor izencitinib makes a Johnson & Johnson opt-in look unlikely.
